Aethox Therapeutics is a preclinical-stage UK-based spin-out from King’s College London building on groundbreaking research into how solid cancers shield themselves from the effects of widely used anti-cancer drugs.
Our inhibitors powerfully increase the effectiveness of chemotherapy drugs. The first in class anti-cancer drug is being prepared for a Phase 1 trial in patients with solid tumours
At Aethox we are on a mission to breakdown cancer’s defences to allow superior treatment responses in patients with solid cancers.
Aethox Therapeutics
Many current cancer treatments are effective only for a limited time, as tumors often adapt and develop mechanisms to protect themselves, neutralizing the drugs' effects and allowing the disease to progress.
At Aethox, our team has uncovered a crucial mechanism by which cancer manipulates immune cells, specifically macrophages, to shield itself from widely used cancer treatments. We have developed small molecule inhibitors that target the activity of these cells, significantly enhancing the effectiveness of cancer treatments. Our first-in-class anti-cancer drug is now being prepared for a Phase 1 trial in patients with solid tumours.
